An investigation into the effects of diindolylmethane (BioResponse DIM®) supplementation in women with low-grade cervical cytological abnormalities

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN47437431

Enrollment

3000

Registered

2005-10-25

Start date

2005-10-25

Completion date

Unknown

Last updated

2018-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical neoplasia. Cancer Cervical

Interventions

Double-blind, placebo-controlled trial. Randomisation is in the ratio 2 DIM®: 1 placebo. Diindolylmethane (BioResponse DIM® - 75 mg capsules) - two capsules daily for 6 months.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women with a first mildly dyskaryotic smear or a second borderline smear taken within the Cervical Screening Wales (CSW) programme will be invited to participate in the trial.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
Reduction in cervical intra-epithelial neoplasia grade 2 (CIN2) or worse.	—

Secondary

Measure	Time frame
Cytology, lesion size, human papillomavirus (HPV) status (all at 6 months).	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026